Le Lézard
Classified in: Health, Science and technology
Subject: PER

Alkahest, Inc. Announces Key Appointments


SAN CARLOS, Calif., Jan. 23, 2018 /PRNewswire/ -- Alkahest, Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing new treatments for neurodegenerative diseases and other age-related conditions, announced today the appointments of Karl G. Trass as Vice President, Regulatory Affairs and Jonas Hannestad, M.D., Ph.D. as Senior Medical Director. 

"We are delighted to further expand our development team as we work to bring innovative medicines to patients with Alzheimer's Disease, Parkinson's Disease and other serious diseases of aging," said Helen Jenkins, Alkahest's Chief Operating Officer.

Karl brings to Alkahest more than 20 years of experience providing global regulatory strategic leadership in both pharmaceutical and biotechnology companies. His experience encompasses building and leading organizational units including regulatory, quality assurance, safety, and manufacturing; managing development and commercial partnerships, contract manufacturing organizations and contract research organizations. Karl joins Alkahest from Tobira Therapeutics where he was Vice President, Regulatory Affairs prior to Tobira's acquisition by Allergan, and he held previous positions of increasing responsibility with Versartis, AbbVie, Neurobiological Technologies, Tularik, and Genentech. Karl received his B.A. in Chemistry from Indiana University.

Jonas has more than 20 years of experience in the field of neuroscience at both academic and biopharmaceutical organizations and is a noted authority in PET imaging in neuroinflammatory and other neurological disorders including the effect of systemic factors on the brain. Dr. Hannestad will maintain his appointment as Adjunct Assistant Professor of Psychiatry at the Yale University School of Medicine, and will be responsible for Alkahest's clinical programs in Alzheimer's and Parkinson's Disease.  Jonas joins Alkahest from Denali Therapeutics and held previous positions at UCB Pharma and Yale University. He received his M.D. from Universidad de Oviedo and a Ph.D. from the University of Messina, and then completed a fellowship at UCLA and residency training in internal medicine and psychiatry at Duke University and Yale University.

About Alkahest
Alkahest is a privately-held clinical-stage company based in San Carlos, California developing treatments for age-related diseases, with an emphasis on cognitive dysfunction and neurodegeneration ? key medical challenges of our generation. The company's breakthrough research has demonstrated that factors in blood plasma are able to reverse the detrimental effects on cognitive functions during in both normal aging and disease models in animals.  Alkahest is developing novel plasma-based products in collaboration with Barcelona, Spain-based Grifols, a global healthcare company and leading producer of plasma therapies.  Alkahest has a pipeline of first-in-class plasma derived, small molecule and recombinant protein products for the treatment of age-related diseases. For further information, see www.alkahest.com.

Contact Information:

Joe McCracken
Vice President Business Development
Alkahest, Inc.
[email protected]

 

SOURCE Alkahest, Inc.


These press releases may also interest you

at 08:15
Keysight Technologies , today announced its intention to acquire the entire issued and to be issued share capital of Spirent Communications PLC (London Stock Exchange Symbol: SPT) ("Spirent") for a cash consideration of 199 pence per Spirent share...

at 08:15
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it will be attending the LSX World Congress (29-30 April) and presenting at Bio?quity Europe (12-14 May). The...

at 08:15
Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety...

at 08:15
Nuvation Bio Inc. , a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms....

at 08:15
StratCap, LLC ("StratCap"), a digital infrastructure asset management company, today announced the execution of a definitive agreement to be acquired by HMC Capital Limited ("HMC"), an Australian Stock Exchange listed alternative asset manager known...

at 08:10
Skyflow, the data privacy vault company, has raised $30 million to extend its Series B funding. Khosla Ventures led the round, joined by prior investors Mouro Capital, Foundation Capital and Canvas Ventures. The investment follows revenue growth of...



News published on and distributed by: